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Abstract
Objective: Central giant cell lesions (CGCL) and peripheral giant cell lesions (PGCL) occur in the jaws and con-
tain osteoclast-like giant cells and mononuclear cells positive for the macrophage marker CD68. The participation 
of immune-inflammatory mechanisms has been proposed in the lesions development. As IL-10 is one of the most 
important anti-inflammatory cytokines and it is also an inhibitory cytokine to macrophage function and bone 
resorption, the purpose of the present study was to investigate its expression together with its receptor (IL-10Rα) 
in CGCL and PGCL. 
Study Design: Six fragments of CGCL and seven fragments of PGCL were obtained by surgical excision. Frozen 
specimens were cut and subjected to immunofluorescence staining using fluorescent-labeled anti-CD68, anti-IL-
10, and anti-IL-10Rα monoclonal antibodies. Microscopic analyses were performed and the percentage of positive 
mononuclear and giant cells for each parameter was obtained.
Results: Our results revealed that all giant cells from CGCL and PGCL were CD68+ and IL-10Rα+ and that the 
majority was also positive for IL-10. More than 50% of the mononuclear cells from both lesions expressed IL-
10Rα and the majority of these cells were CD68+ and IL-10+.
Conclusion: Considering that IL-10 has inhibitory effects on the pathologic processes related to the development 
of the oral giant cell lesions, the high frequencies of cells producing this cytokine seems contradictory to these 
lesions growth. Investigation about the production of inflammatory cytokines as well as the IL-10 signaling path-
ways in oral giant cell lesions is required to elucidate the immunopathology of CGCL and PGCL. 
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Introduction
The central giant cell lesion (CGCL) is a reactive bone 
lesion that occurs most commonly in the anterior por-
tion of the mandible of young patients (1). Radiologi-
cally, the lesions show an unilocular or a multilocular 
radiolucent lesion and presents a variable clinical be-
havior and unpredictable course. Some lesions show a 
slow growth and do not recur, while others exhibit rapid 
growth, root resorption, cortex perforation, and a ten-
dency to recur after excision (1,2).
The peripheral giant cell lesion (PGCL) is a relatively 
common reactive lesion that occurs on the gingiva or 
edentulous alveolar ridge, showing as a red or reddish-
blue nodular mass. Most lesions grow slowly, can de-
velop at almost any age, and show highest prevalence in 
females. The development of PGCL is usually related to 
the presence of local irritating factors and arises from 
the connective tissue of the gingiva or the periosteum of 
alveolar ridge (3). 
Histologically, both lesions are characterized by the 
presence of numerous multinucleated giant cells em-
bedded in a fibrocellular stroma showing blood vessels, 
extensive hemorrhagic areas, and newly formed osteoid 
or bone (1,4). Recently, it has been suggested that mono-
nuclear cells from CGCL and PGCL comprise mainly 
osteoclast precursors, macrophages, and some osteob-
lastic cells (5). The giant cells from both lesions show 
phenotypic and functional characteristics of osteoclasts 
(6,7). Previous studies have shown that the mononuclear 
cells from these giant cell lesions may be responsible 
for the formation of the giant cells (7,8). However, the 
relationship of giant cells with mononuclear cells has 
not been fully elucidated.
The presence of osteoclast-like cells intermingled with 
mononuclear cells suggests that immune-inflammatory 
mechanisms may participate in the development of these 
lesions. Previous studies demonstrated alterations of the 
frequencies of circulating monocytes and lymphocytes 
that produce inflammatory and anti-inflammatory cy-
tokines, including IL-10, in individuals with CGCL (9). 
IL-10 is one of the most important anti-inflammatory 
cytokines and it is also an inhibitory cytokine to mac-
rophages function and bone resorption (10,11). Based 
on the fact that circulating monocytes can be recruited 
from blood to inflammatory sites and on the fact that the 
production of cytokines in these sites represents an im-
portant mechanism of control of tissue local alterations 
(12), we investigated the expression of the immunossu-
pressive cytokine IL-10 and its receptor (IL-10Rα) in 
mononuclear and giant cells from CGCL and PGCL.
Materials and Methods
Patients. Six cases of CGCL and seven cases of PGCL 
were analyzed in this study. The diagnosis, age, sex, lo-
cation, size, radiographic aspects, and treatment of the 
samples are presented in (Table 1). All patients were 
volunteers, and informed consent was obtained from 
all individuals prior to collection of lesion material. 
Diagnosis of CGCL or PGCL was performed based on 
clinical, radiographic, and histopathological analysis. A 
fragment of each lesion obtained by surgical excision 
was maintained in a 30% sucrose solution for approxi-
mately 30 min at 4oC; then it was transferred to Tissue-
Tek® O.C.T.™ Compound freezing medium (Sakura) 
and immediately placed in a –20oC freezer for 1 hour. 
The material was stored at –80oC until analysis. This 
study was approved by the local Ethical Committee.
Histological and immunofluorescence staining. Indi-
vidual 4- to 5-µm cryosections were placed in saline-
precoated slides (VWR Scientific) and fixed for 10 min 
Patient Diagnosis Age(yr) Sex Location 
Size 
(mm) Radiographic aspects Treatment 
1 CGCL 11 M mandible 30 multilocular radiolucent lesion curettage 
2 CGCL 9 F mandible 30 multilocular radiolucent lesion curettage 
3 CGCL 46 M mandible 40 multilocular radiolucent lesion curettage 
4 CGCL 41 F mandible 10 unilocular radiolucent lesion curettage 
5 CGCL 11 F mandible 40 multilocular radiolucent lesion curettage 
6 CGCL 19 M mandible 20 bilocular radiolucent lesion curettage 
7 PGCL 57 M edentulous lower ridge 10 alveolar crest resorption surgical excision 
8 PGCL 37 M edentulous lower ridge 20 alveolar crest resorption surgical excision 
9 PGCL 21 F lower gingiva 15 none surgical excision 
10 PGCL 25 F lower gingiva 30 alveolar crest resorption surgical excision 
11 PGCL 22 F upper gingiva 50 none surgical excision 
12 PGCL 45 M edentulous upper ridge 25 none surgical excision 
13 PGCL 21 M lower gingiva 20 alveolar crest resorption surgical excision 
Table 1. Clinical information on peripheral giant cell lesion (PGCL) and central giant cell lesion (CGCL) cases selected for the study.
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with acetone. Slides were incubated with phosphate-
buffered saline for 15 min and subjected either to hema-
toxylin-eosin staining or to immunofluorescence using 
specific monoclonal antibodies. Standard hematoxylin-
eosin staining was performed to ensure tissue integrity 
as well as for evaluation of the location of cellular areas 
containing giant cells. Immunofluorescence reactions 
involved incubation with fluorescein isothiocyanate 
(FITC)-labeled monoclonal antibody anti-CD68 (clone 
Ki-M7, Caltag, Burlingane, CA, 1:30 dilution) and phy-
coerythrin (PE)-labeled monoclonal antibodies anti-IL-
10 (clone JES3-9D7, Caltag, Burlingane, CA, 1:20 dilu-
tion). Sections were incubated with antibody mixtures 
overnight at 4oC. For the IL-10Rα staining, sections 
were incubated with monoclonal antibody anti-IL-10Rα 
(clone 37607.11, R&D Systems, Minneapolis, MN, 1:40 
dilution) overnight at 4oC, washed with phosphate-
buffered saline, and incubated with rodamine-labeled 
antibody anti-mouse immunoglobulin (Jackson Im-
munoResearch Laboratories, Inc – Pennsylvania, USA, 
1:200 dilution) for 1 hour at room temperature. After 
staining, preparations were extensively washed with 
phosphate-buffered saline, counterstained with 4’,6’-
diamidino-2-phenylindole (DAPI), and mounted using 
Hydromount (National Diagnostics). Slides were kept 
at 4oC, protected from light, until acquisition in a laser 
scanning confocal microscope (Meta-510 Zeiss). Iso-
type controls were analyzed separately to confirm the 
lack of nonspecific staining.
Microscopy analysis. Imaging was performed with a 
Meta-510 Zeiss laser scanning confocal system run-
ning LSMix software with an oil immersion Plan-
Apochromat objective (63X, 1.2 numerical aperture). A 
water-cooled argon UV laser (488nm) or a neon laser 
was used to excite the preparation (through its 488nm 
line or 543nm line), and light emitted was selected with 
band-pass filters (20/80 for DAPI or 503/30 for FITC) 
or long-pass filter 560 for PE and rodamine. For each 
section, cellular areas containing giant cells were se-
lected for analysis. Within these areas, a minimum of 
ten images (fields) was collected. Image analysis and 
processing were performed with LSMix, Confocal As-
sistant, Adobe Photoshop, and Image Tool software. 
Analyses were performed by counting the total number 
of mononuclear or giant cells in the ten fields acquired 
(DAPI stain cellular nucleus), the number of FITC or 
PE single-positive cells and the number of double-pos-
itive cells, for CD68 and IL-10 staining. For IL-10Rα 
staining, the total number of cells and the number of 
rodamine-positive cells were obtained. The counts were 
performed blindly, the results were expressed as the 
percentage of positive mononuclear and giant cells per 
section for each parameter for each patient, and then the 
values were averaged for each group.
Statistical analysis. Statistical analysis of the data 
was performed using BioEstat 3.0 statistical software. 
The comparisons of percentage for a given parameter 
between the groups were performed using the non-
parametric Mann-Whitney test. Correlation analysis 
between the percentage of IL-10+ cells and IL-10Rα+ 
cells into each group was performed using the Spear-
man test. Results were considered statistically different 
when the analysis returned a P value of <0.05.
Results
High frequencies of mononuclear and giant cells from 
CGCL and PGCL express IL-10. Evaluation of IL-10 
expression by mononuclear and giant cells from CGCL 
and PGCL were performed by microscopy analysis of 
sections submitted to immunofluorescence reactions, 
as described in Materials and Methods. The average 
number of total cells counted was 27 for giant cells and 
747 for mononuclear cells in each case. Mononuclear 
and giant cells from both lesions express IL-10 (Fig. 
1A and B). More than 80% of the mononuclear cells 
in CGCL and approximately 100% of the mononuclear 
cells in PGCL were IL-10+ (Table 2). Approximately 
80% of the giant cells in CGCL and 100% of giant cells 
in PGCL were IL-10+. All giant cells from both lesions 
were CD68+. High frequencies of CD68+ mononuclear 
cells were observed in CGCL and PGCL groups (Table 
2).
Evaluation of the cellular sources of IL-10 demonstrated 
that CD68+ mononuclear cells are the main cell popula-
tion expressing this cytokine in both CGCL and PGCL 
(Table 2). Whereas the total expression of IL-10 was not 
Fig. 1. Expression of IL-10 and IL-10Rα in CGCL and PGCL cases. 
(A and B) Representative images from confocal microscopy analyses 
of CD68 and IL-10 expression in CGCL and PGCL cases respec-
tively. Overlays for CD68 (green), IL-10 (red), and DAPI (blue) are 
shown, with inset of high-power detail of IL-10 positive mononu-
clear cells. Cells that are double positive for CD68 and IL-10 show 
a yellow or orange-red cytoplasm. (C and D) Representative images 
from confocal microscopy analyses of IL-10Rα expression in CGCL 
and PGCL cases respectively. Overlays for IL-10Rα (red) and DAPI 
(blue) are shown.
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statistically different when CGCL and PGCL were com-
pared, the frequency of IL-10+ cells in CD68+ mononu-
clear population was higher in PGCL than CGCL group 
(Table 2).
High frequencies of mononuclear and giant cells from 
CGCL and PGCL express IL-10Rα. Evaluation of IL-
10Rα expression by mononuclear and giant cells from 
CGCL and PGCL was performed by microscopy analy-
sis of sections submitted to immunofluorescence reac-
tions, as described in Materials and Methods. Mononu-
clear and giant cells from both lesions express IL-10Rα 
(Fig. 1C and D). While all giant cells in CGCL and 
PGCL express IL-10Rα, approximately 60% of mono-
nuclear cells in both lesions were positive for IL-10Rα 
(Table 2).
Discussion 
In this work, we demonstrate that cells from central 
giant cell lesion (CGCL) and peripheral giant cell le-
sion (PGCL) are able to produce the anti-inflammatory 
cytokine IL-10 and to express the IL-10Rα. When we 
quantified the cells that produce IL-10 in the lesions, we 
observed that most of the mononuclear and giant cells 
from CGCL and almost all cells from PGCL were IL-10 
producers.
IL-10 is one of the most important anti-inflammatory 
cytokines, exerting a high inhibitory activity on mac-
rophage function (10). Many mononuclear cells from 
CGCL and PGCL show characteristics of macrophages 
or osteoclast precursors and these cells do not show 
strong proliferative activity (5,13). As the lesions are 
continuously developing and the osteoclast precursors 
are recruited from the blood (14), the increasing celull-
arity of the lesions depends directly on the recruitment 
of monocytic cells from the blood. The macrophages 
produce chemokines and cytokines that stimulate the 
expression of adhesion molecules by the endothelial 
cells (15). These phenomena are essential for the leu-
kocyte recruitment from the blood to the inflammatory 
sites. IL-10 inhibits production of these chemokines and 
cytokines by macrophages, thus decreasing the cell re-
cruitment from peripheral blood (10). 
In addition to IL-10 inhibitory effects on leukocyte re-
cruitment, IL-10 also inhibits M-CSF production (10). 
The M-CSF is a key mediator of differentiation of os-
teoclasts precursors in mature osteoclasts (14). The in-
hibition of the macrophages functions by IL-10 leads to 
the suppression of the production of IL-12, a cytokine 
that stimulates T lymphocytes to produce IFN-γ, which 
is the main macrophage activating factor (16). In vitro 
studies demonstrated that the mononuclear cells from 
human blood only form multinucleated giant cells in the 
presence of  IFN-γ. IFN-γ induces the expression of the 
adhesion molecule LFA-1 by the monocytic cells. This 
molecule is necessary for the fusion and formation of 
giant cells (17). 
IL-10 inhibits the proliferation and differentiation of 
osteoclasts precursors in murine mononuclear cells 
culture, even in the presence of osteoblasts (11). This 
cytokine also inhibits the production of cytokines 
that stimulate bone resorption, such as IL-1, IL-6 and 
TNF-α, by the macrophages (10).
The high frequency of cells that produce IL-10 in the 
CGCL and in the PGCL may reflect an attempt to inhib-
it the mechanisms that lead to the uncontrolled recruit-
ment of mononuclear cells and to the destruction of tis-
sue. It is possible that the cells from CGCL and PGCL 
produce high levels of pro-inflammatory cytokines. 
Thus, monocytic cells recruited from the blood to the 
lesion sites could respond to these stimuli by produc-
ing IL-10. Certainly, many soluble factors are involved 
in the development of CGCL and PGCL, in which the 
production of IL-10 by itself is not sufficient to assure 
the modulation of the pathologic process related to the 
pathogenesis of these lesions. 
The elevated frequencies of IL-10 positive cells in both 
lesions (more than 80%) are significantly higher than 
the ones observed in active infectious lesions as in mu-
cosal leishmaniasis (18). As CGCL and PGCL have an 
unknown etiology, we do not know which stimuli lead 
to the macrophages activation, inducing IL-10 produc-
tion.
Concerning the contribution of the CD68+ population 
to the total production of IL-10, we observed that this 
population is the main source of IL-10 in both lesions 
studied. In the present study, 20% of the CGCL mono-
nuclear cells and 2% of the PGCL cells were CD68 
Table 2. Percentage of IL-10-, CD68-, and IL-10Rα-positive mononuclear cells and relative contribution of the CD68+ population to the 
production of IL-10 in central giant cell lesion (CGCL) and peripheral giant cell lesion (PGCL) cases.
Parameter CGCL (n=6) PGCL (n=7)  
 Mean Median Minimum Maximum Mean Median Minimum Maximum P value 
% total IL-10+ cells 80.0 91.6 14.3 99.7 98.8 100 95.4 100 0.032 
% total CD68+ cells 81.5 90.9 34.4 96.0 97.8 99.7 92.9 100 0.010 
% IL-10+ in CD68+ cells 86.5 97.6 31.5 100 99.9 100 99.8 100 0.030 
% total IL-10RĮ+ cells 60.6 63.4 26.4 92.4 67.4 66.2 39.1 84.2 0.886 
Med Oral Patol Oral Cir Bucal. 2011 Jul 1;16 (4):e488-92.                                                                                                                                                            IL-10 and IL-10R in giant cell lesions
e492
 References with links to Crossref - DOI    
negative. These cells may be another leukocyte type or 
osteoblastic cells, as previously described by other au-
thors (5,6). About 50% of the CD68 negative mononu-
clear cells from both, CGCL and PGCL, produce IL-10 
(data not showed). T and B leukocytes, NK cells and 
osteoblasts also produce IL-10 (10,19). It is possible that 
soluble factors present in the lesions stimulate other cell 
types to produce IL-10. 
In order to investigate whether CGCL and PGCL cells 
are able to respond to IL-10, we evaluated the IL-10Rα 
expression. All giant cells and about 60% of mononu-
clear cells from both lesions were IL-10Rα positive. 
This receptor is expressed by a variety of cells of the 
immune system, especially by macrophages (20), but 
there are no studies about the expression of this receptor 
by giant cells or osteoclasts. Our findings suggest that 
most cells from both lesions (CGCL and PGCL) are able 
to respond to the IL-10, although the strong inhibitory 
action of IL-10 does not correspond with the develop-
ment of these lesions. The mechanisms that control the 
expression of the IL-10Rα are not well established.
Considering that IL-10 has inhibitory effects on the 
pathologic processes related to the development of the 
oral giant cell lesions, the high frequencies of cells that 
produce this cytokine seems contradictory to these le-
sions’ growth. One possibility is that the lesion cells 
present alterations on their molecular signaling pathway 
activated by the IL-10. Another possibility is that the 
production of pro-inflammatory cytokines is sufficient-
ly high to supplant the inhibitory effects of IL-10. Inves-
tigation about the production of inflammatory cytokines 
as well as the IL-10 signaling pathways in oral giant cell 
lesions is required to elucidate the immunopathology of 
CGCL and PGCL.
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